Compare
Milestone Pharmaceuticals Inc. vs Arbutus Biopharma Corp vs Journey Medical Corp vs Eton Pharmaceuticals, Inc.
| Latest fiscal year | Milestone Pharmaceuticals Inc. MIST | Arbutus Biopharma Corp ABUS | Journey Medical Corp DERM | Eton Pharmaceuticals, Inc. ETON |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $14.08M | $61.24M | $79.95M |
| Revenue growth (YoY) | n/a | +128.2% | +11.1% | +104.9% |
| Gross margin | n/a | n/a | 65.8% (computed) | 53.5% |
| Operating margin | n/a | -271.0% | -13.3% | -1.1% |
| Net margin | n/a | -237.9% | -18.7% | -5.8% |
| Net income | -$63.06M | -$33.50M | -$11.43M | -$4.60M |
| EPS (Diluted) | -$0.75 | -$0.17 | -$0.47 | n/a |
| Operating cash flow | -$49.04M | -$39.64M | -$12.44M | $10.52M |
| Free cash flow | -$49.34M | -$39.64M | n/a | $10.19M |
| Cash & equivalents | $73.05M | $18.01M | $24.09M | $25.94M |
| Total assets | $113.56M | $94.62M | $94.59M | $92.11M |
| Total liabilities | $71.79M | $18.04M | $62.74M | $65.96M |
| Shareholders' equity | $41.77M | $76.58M | $31.85M | $26.15M |
| Return on year-end equity | -151.0% | -43.7% | -35.9% | -17.6% |
| Shares outstanding | 106.24M | 192.53M | n/a | 27.05M |
Revenue, most recent five fiscal years
| Fiscal year | Milestone Pharmaceuticals Inc. | Arbutus Biopharma Corp | Journey Medical Corp | Eton Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | $14.08M Ended 2025-12-31 | $61.24M Ended 2025-12-31 | $79.95M Ended 2025-12-31 |
| 1 year earlier | n/a | $6.17M Ended 2024-12-31 | $55.13M Ended 2024-12-31 | $39.01M Ended 2024-12-31 |
| 2 years earlier | n/a | $18.14M Ended 2023-12-31 | $59.66M Ended 2023-12-31 | $31.64M Ended 2023-12-31 |
| 3 years earlier | n/a | $39.02M Ended 2022-12-31 | $71.00M Ended 2022-12-31 | $21.25M Ended 2022-12-31 |
| 4 years earlier | n/a | $10.99M Ended 2021-12-31 | $63.13M Ended 2021-12-31 | $21.83M Ended 2021-12-31 |